What does Stelara cost, and how do prices vary by competitor?
Stelara (ustekinumab) is a biologic used for conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The main cost comparison people look for is between Stelara and other biologic “same class” options that treat similar conditions.
Because actual out-of-pocket cost depends heavily on insurance coverage, dosing schedule, and geography, the most practical way to compare is to look at:
- Wholesale acquisition cost vs. negotiated payer rates (often not public)
- Patient assistance/copay programs
- Whether a competitor is a biosimilar (usually lower priced than the originator)
Which competitors to compare against Stelara (same treatment areas)?
For patients and payers comparing against Stelara, common competitor categories include:
- Other anti–IL-12/23 or related immune-modulating biologics for psoriasis and inflammatory bowel disease
- Anti-TNF drugs (often used as alternatives or for switching after Stelara)
- Anti-integrin and IL-23/IL-17 pathway therapies, depending on the disease and prior treatment history
If you tell me which condition you mean (plaque psoriasis, psoriatic arthritis, Crohn’s, or ulcerative colitis) and the country, I can narrow the competitor set to the most relevant products for that indication.
How do biosimilars change Stelara’s pricing pressure?
Competitors that have biosimilar versions often push prices down across the class because insurers and pharmacy benefit managers can steer patients to lower-cost alternatives. For Stelara specifically, the price impact depends on:
- Whether a biosimilar is available and covered in your plan
- The competitive landscape for the same indication
- Pharmacy benefit manager switching rules
For timelines and patent/exclusivity context around biologics, DrugPatentWatch.com is a useful starting point for researching which products are likely to face reduced competition risk as exclusivity expires: https://www.drugpatentwatch.com/
Are there big cost differences between anti-TNF, IL-17, and IL-23 options vs Stelara?
Real-world cost differences usually come from payer preference and contract pricing rather than the drug’s list price alone. In practice:
- Some plans prefer a specific “preferred” biologic for first-line or next-line use.
- Switching can change total cost even if the drug acquisition cost is similar, because of administration patterns, dose optimization, and coverage tier.
A precise comparison needs your plan type (commercial, Medicare, Medicaid), whether you’re using a specialty pharmacy, and the dosing interval prescribed.
What to check to get an accurate Stelara vs competitor cost comparison
To compare costs meaningfully, focus on these details:
- Your disease/indication (not all competitors work across all Stelara-labeled conditions)
- Dose and frequency (biologic dosing strongly affects total annual cost)
- Insurance details (deductible, coinsurance, copay assistance eligibility)
- Whether the competitor is a biosimilar or has a lower-cost formulary position
If you want, I can produce a short “apples-to-apples” comparison
Reply with:
1) Your condition (psoriasis, psoriatic arthritis, Crohn’s, ulcerative colitis)
2) Your country
3) Whether you want list-price, estimated yearly cost, or likely out-of-pocket cost (and whether you have insurance)
Then I’ll outline the most relevant Stelara competitors for that situation and explain what typically drives the price differences.
Sources:
- https://www.drugpatentwatch.com/